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Background-—Current guidelines recommend use of the aldosterone-renin ratio (ARR) for the case detection of primary
aldosteronism followed by confirmatory tests to exclude false-positive results from further diagnostic workup. We investigated the
hypothesis that this could be unnecessary in patients with a high ARR value if the quantitative information carried by the ARR is
taken into due consideration.
Methods and Results-—We interrogated 2 large data sets of prospectively collected patients studied with the same predefined
protocol, which included the captopril challenge test. We used an unambiguous diagnosis of aldosterone-producing adenoma as
reference index. We also assessed whether the post-captopril ARR and plasma aldosterone concentration fall furnished a
diagnostic gain over baseline ARR values. We found that the false-positive rate fell exponentially, and, conversely, the specificity
increased with rising ARR values. At receiver operating characteristics curves and diagnostic odds ratio analysis, the high baseline
ARR values implied very high positive likelihood ratio and diagnostic odds ratio values. The baseline and post-captopril ARR showed
similar diagnostic accuracy (area under the receiver operating characteristics curve) in both the exploratory and validation cohorts,
indicating lack of diagnostic gain with this confirmatory test (between-area under the curve difference, 0.005; 95% CI, 0.031 to
0.040; P=0.7 for comparison, and 0.05; 95% CI, 0.061 to 0.064; P=0.051 for comparison, respectively).
Conclusions-—These results indicate that the ARR conveys key quantitative information that, if properly used, can simplify the
diagnostic workup, resulting in saving of money and resources. This can offer the chance of diagnosis and ensuing adrenalectomy
to a larger number of hypertensive patients, ultimately resulting in better control of blood pressure. ( J Am Heart Assoc. 2017;6:
e005574. DOI: 10.1161/JAHA.117.005574.)
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T he recent Lancet Commission on Arterial Hypertensioncalled attention to the disastrous status of blood
pressure (BP) control worldwide and included the search for
secondary hypertension among the 9 key steps to combat
high BP. Primary aldosteronism (PA) is the most prevalent
endocrine cause of arterial hypertension. According to all
guidelines, it should be screened with the aldosterone-renin
ratio (ARR),1–3 although the guidelines do not specify which
ARR cut-off value should be used to define a positive result.
However, in clinical practice the test is considered positive
when its value exceeds a given cutoff, commonly placed
between 20 and 40 (in [ng/dL]/[ng/mL per hour] for plasma
aldosterone concentration [PAC] and plasma renin activity
[PRA]).1,4,5
Such liberal cutoffs maximize sensitivity, but generate
many false positives. For example, in the Primary Aldoster-
onism Prevalence in hYpertension (PAPY) Study, by using a
cutoff of 30, the false positive (FP) rate was 18%.4 The latter
must be excluded from the further invasive and expensive
subtyping, which requires adrenal vein sampling (AVS), a
costly and minimally invasive procedure available only in
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highly specialized referral centers.1,3,5 Hence, to the end of
selecting the patients for AVS, both the Endocrine Society
and the Japanese guidelines concur in supporting the use of
confirmatory tests.
Algorithms entailing confirmatory tests may carry some
limitations in that they have theoretical drawbacks and
furthermore are not evidence based.6 For example, the basic
assumption that aldosterone is autonomous (from angioten-
sin II) secretion in all aldosterone-producing adenoma (APA)
patients is not proven. In the seminal study that introduced
the saline infusion test, only 5 patients had an APA by
currently accepted criteria, and, moreover, 2 of them
showed an increase of PAC with standing up indicating
responsiveness to angiotensin II.7 The existence of angio-
tensin II-responsive APA in up to 70% of the cases has been
thereafter documented by multiple independent studies.8–11
Furthermore, the 2 most popular confirmatory tests, the
captopril challenge and the saline infusion, when assessed
prospectively in a large cohort of consecutive patients,
showed such an overlap of PAC responses between patients
with and without APA that abated their value for individual
patients discrimination11 and disproved the basic assump-
tion of angiotensin II independence.
The systematic use of confirmatory tests in clinical
practice increases times, complexity, and costs of the
diagnostic workup, thus contributing to the underdiagnosis
of PA. A simplification of the diagnostic algorithm would
therefore be a crucial step for improving the detection rate of
PA, which can ultimately result in more patients referred for
adrenalectomy or for specific therapies, which are highly
efficacious12,13 and cost-effective.14
The surgically curable APAs usually feature a more florid
biochemical phenotype than the medically treatable bilateral
adrenal hyperplasia (BAH).4 Hence, high ARR values point to
an APA subtype, more than to BAH.4,15 We therefore
hypothesized that: (1) the ARR carries quantitative informa-
tion, which wanes when its results are dichotomized as
positive or negative, and (2) high ARR values could be
associated with a high likelihood of APA. If verified, these
hypotheses would indicate no need for further confirmation
and the possibility for the patients with high ARR values to
proceed directly to AVS. In line with this proposition,
recognizing the burden of the systematic undertaking of
confirmatory tests, the recently released guidelines suggest
to proceed directly to AVS in patients with a PAC value
>20 ng/dL (550 pmol/L), plasma renin below detection
levels, and concurrent hypokalemia,1 albeit as recommenda-
tion of class 2 with very-low-quality evidence.
Hence, we set out to determine whether increasing ARR
values allows unambiguous identification of an APA with a
high diagnostic specificity. We also sought for investigating
the diagnostic gain of the captopril challenge test over
baseline ARR as a function of different ARR cutoffs.
Materials and Methods
The protocol of the Aldosterone-Renin Ratio for Primary
Aldosteronism (AQUARR) study was already published16;
hence, it will be only briefly recalled here. The study entailed
2 large cohorts of referred prospectively recruited hyperten-
sive patients, all of which underwent measurement of the ARR
at baseline and after the captopril challenge test. All patients
provided an informed written consent and the protocol was
approved by the ethics committee of the University of Padua
(Padua, Italy).
Exploratory Analysis
The exploratory analysis was performed in the PAPY Study
data set, which was carried out between 2000 and 20054 and
prospectively recruited 1125 consecutive patients newly
diagnosed with hypertension, who were referred to special-
ized centers for diagnosis and treatment of hypertension.
Details on exclusion criteria, screening procedure, pharma-
cological treatment, and diagnosis are given in Data S1.
By protocol PA was diagnosed if patients had an ARR ≥40
at baseline and/or an ARR ≥30 post-captopril (method 1)
and/or a logistic discriminant function score ≥0.50.17,18 To
avoid a factitious inflation of the ARR value when PRA values
were <0.20 ng/mL per hour, they were fixed at 0.20 ng/mL
per hour for the ARR calculation.
The study followed the STARD Statement for Reporting
Diagnostic Accuracy Studies, according to which diagnostic
approaches/tests should be evaluated against a clinical
reference standard or a gold standard.19 Thus, recognizing
that discrimination of BAH from low-renin primary (essential)
hypertension is arbitrary,20 and that a diagnosis of PA can be
made unambiguously only for APA, it was decided beforehand
to use the diagnosis of APA as the gold standard. Accordingly,
all the following “4 corners criteria” had to be fulfilled for
diagnosing an APA: (1) a biochemical finding of PA; (2)
lateralization of aldosterone secretion either at AVS or at 131I-
norcholesterol dexamethasone-suppressed adrenocortical
scintigraphy; (3) adenoma demonstration at pathology assess-
ment; and (4) evidence of normokalemia and cure or
improvement of hypertension at follow-up at least 120 days
after adrenalectomy. Cure was defined as a BP <140/
90 mm Hg, for systolic and diastolic, respectively, without
antihypertensive medications; improvement entailed systolic
and diastolic BP <140/90 mm Hg on the same or a
decreased number and/or of defined daily doses of medica-
tions.20 Patients with biochemical PA without lateralized
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aldosterone excess were held to have BAH. Upon completion
of the diagnostic workup and follow-up, an adjudication
committee established the final diagnosis.
Validation Phase
Consecutive white patients referred to the ESH Excellence
Hypertension Center of the University of Padua between
January 2012 and February 2015 were prospectively recruited
in the validation cohort. They were recently diagnosed with
hypertension and, after publication of the PAPY Study results,4
all were systematically screened for secondary hypertension.1
All underwent the same workup described above for the
exploratory data set under carefully standardized conditions,
the only differences being a centralized measurement of all
biochemical indexes, a longer (4 weeks) minimum wash-out
period (for diuretics, beta-blockers, angiotensin-converting
enzyme inhibitors, and angiotensin II receptor type 1 antago-
nists), no consideration to the postcaptopril PRA and PAC value
for the diagnosis, and systematic use of AVS when indicated.1
Exclusion criteria entailed a previous diagnosis of secondary
hypertension, including the Familial Hyper-aldosteronism-1, as
identified by genetic testing.21
Of the 1266 patients initially recruited, 190 had to be
excluded to prevent any confounding effect on the analysis
of diagnostic accuracy: 153 because of unfeasible washout
due to very high BP levels and/or target organ damage, and
37 with PA owing to unfulfilled 4 corners criteria because of
either lack of subtyping data (n=31) or refused adrenalec-
tomy (n=6) in spite of lateralized aldosterone excess at AVS.
Thus, 1076 patients were available for the final analysis
(Figure 1).
PRA, PAC, Na+, and K+ serum levels and 24-hour urinary
excretion were centralized and measured in a certified
(International Organization for Standardization [ISO] 9001)
laboratory. Normal values and within- and interassay coeffi-
cient of variation have been reported.4,22 PA and APA were
diagnosed by the aforementioned criteria by an adjudication
committee (G.M., G.P.R.), with the only relevant difference
that PA diagnosis was made based on the unstimulated ARR
level ≥40 regardless the post-captopril data. For the purpose
of this study, the patients with lateralized aldosterone excess
at AVS, who had a biochemical correction of PA and showed
an improvement/cure of hypertension after adrenalectomy,
but at pathology were found to have unilateral multinodular
hyperplasia, were included in the APA group.
n = 1113
n = 153 
due to
confounding therapy
n = 37 PA patients
due to
lack of subtyping
or 
missing 4 corners criteria 
because adrenalectomy 
was not performed
exclusion
exclusion
Exploratory Phase
(Multi-center data set of the PAPY 
Study)
(n=1125)
Validation Phase
(Single-center data set 
Padua Study)
(n = 1266)
Accuracy* of the ARR 
(using the diagnosis of APA by the 4 corners criteria
as reference index)
n = 1076
Figure 1. Flow chart of the AQUARR (Aldosterone-Renin Ratio for Primary Aldosteronism) study. *The
accuracy of the aldosterone-renin ratio (ARR) was determined by analysis of the area under the receiver
operating characteristics curve, positive and negative likelihood ratio, diagnostic odds ratio), and error rate.
The optimal cut-off values were established by Youden index analysis. APA indicates aldosterone-producing
adenoma; PA, primary aldosteronism; PAPY, Primary Aldosteronism Prevalence in hYpertension.
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Statistical Analysis
Transformation (log or square root) of skewed quantitative
variables was exploited to achieve a normal distribution, as
appropriate, before statistical analysis. One-way ANOVA
followed by Bonferroni’s post-hoc test, or t test, were used
to compare quantitative variables among/between groups.
The distribution of categorical variables was compared by chi-
square analysis.
The operative features of the ARR (sensitivity, specificity,
positive and negative likelihood ratios, and diagnostic odds
ratio [DOR]) and identification of optimal cut-off values were
calculated using the conclusive diagnosis of APA, as defined
above, as reference.19
The positive and negative likelihood ratio, error rate, and
DOR were calculated to estimate the test accuracy for
identifying patients with APA. The positive likelihood ratio (eg,
the ratio of probability of a positive test result in patients with
and without disease) was calculated as sensitivity/(1speci-
ficity); the negative likelihood ratio (eg, the ratio of probability
of a negative test result in patients with and without disease)
was estimated as (1sensitivity)/specificity. The error rate
was calculated as follows:
PðT jDþÞ  PðDþÞ þ PðTþ jDÞ  PðDÞ
where P(T |D+) stands for the false negative (FN) rate, P(D+)
is the rate of diseased patients, P(T+ |D) stands for the FP
rate, and P(D) is the rate of nondiseased patients.
The DOR, a prevalence-independent indicator of test
performance, was computed as the odds of positivity among
diseased patients divided by the odds of positivity among
nondiseased patients. It can also be defined as the ratio of the
odds of disease in test positives relative to the odds of
disease in test negatives. Its values range from zero to infinity,
with a value of 1 indicating that the test does not discriminate
between patients with and without disease and higher values
indicating progressively better discriminatory performance of
the test.23,24
The area under the receiver operating characteristics
(ROC) curve was used to estimate the accuracy of the test for
identification of APA. The Youden Index (J), which defines the
maximum potential effectiveness of a biomarker, can be
formally defined as J = max (c) {Sensitivity (c) + Specificity (c)
− 1}. The cut-point that achieves this maximum is referred to
as the optimal cut-point (c*) because it is the cut-off that
optimizes the biomarker’s differentiating ability when equal
weight is given to sensitivity and specificity. Hence, C* was
used to identify the baseline and post-captopril ARR cut-off
values corresponding to the best combination of sensitivity
and specificity.
We first plotted specificity and FP rate for the diagnosis of
APA as a function of the ARR values in both data sets, as a
preliminary inspection of the quantitative value of the baseline
ARR (Figure 2). Next we examined the ARR cut-off values
corresponding to a 5% FP rate and to 1% step-wise decreases.
To further verify the robustness of these findings, acknowl-
edging that some assays have lower limits of detection of
PRA, a sensitivity analysis was carried out using a minimum
cutoff for PRA (0.10 ng/mL per hour).
To determine the diagnostic gain yielded by the captopril
challenge test, we compared the ROC areas under the curve
(AUCs) of baseline and post-captopril ARR (method 1) and of
baseline and post-captopril PAC decrease (method 2).1
Significance was set at P<0.05. For the statistical analysis,
we used the SPSS (version 23 for Mac; IBM Italy Spa, Rome,
Italy), GraphPad Prism (version 6.00 for Mac; GraphPad
Software, La Jolla, CA), and MedCalc (version 8.1.1.0;
MedCalc Software, Mariakerke, Belgium) software.
Figure 2. Diagnostic yield of the aldosterone-renin ratio (ARR)
values. The plot shows that increasing ARR values are associated
with an exponential increase of specificity and an exponential
decrease of false negative (FN) rate for identification of
aldosterone-producing adenoma patients in the exploratory (A)
and validation (B) cohort. FP indicates false positive.
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Results
Baseline Characteristics of the Patients
Table S1 shows the baseline characteristics of the 1125 PAPY
Study patients divided by diagnosis. As described, 84% in the
BAH group and more than 50% in the APA group did not have
hypokalemia.4 However, APA patients showed a more-florid
PA phenotype than BAH patients, as indicated by higher PAC
and ARR and lower serum K+. Compared to PH patients, APA
patients were older, had higher systolic BP, and lower serum
K+; they also showed the expected higher PAC, and lower
PRA, which translated into higher ARR values.
Rate of PA was slightly lower in the validation (6.9%) than
in the exploratory cohort (11.2%), even though the overall
baseline characteristics of the patients in the validation
cohort (Table 1) closely mimicked those of the exploratory
data set. This expected finding is readily explained by the fact
that after the publication of the PAPY Study in 2006, a
systematic screening was implemented at our center. Com-
parison of the features of the 3 diagnosis groups between the
exploratory and the validation data set showed only slight
differences of age, estimated glomerular filtration rate,
baseline PRA, PAC, and ARR (Figures S1 through S5) and
overall less spread values reflecting the single-center nature
of this cohort. Baseline and post-adrenalectomy APA patients’
features are provided in Table S2.
Diagnostic Yield of the ARR at Different Cut-Off
Values
Progressively increasing ARR values were associated with an
exponential increase of specificity for identification of APA
patients and, conversely, with an exponential decay of the FP
rate, both in the exploratory and in the validation data set,
albeit with better results in the latter (Figure 2). Table S3 and
Table 2 show the specificity, FP rate, positive and negative
likelihood ratio, and DOR in the exploratory and validation
data sets at prespecified ARR cutoffs.
The ROC AUC, an overall measure of the ARR accuracy for
the diagnosis of APA (Figure 3), was higher (P<0.001) than
the identity line AUC (0.500) in both data sets, with a trend to
lower values in the exploratory (0.878; 95% CI, 0.821–0.923)
than in the validation data set (0.980; 95% CI, 0.960–1.000;
P<NS [not significant] for comparison). However, the ARR
value that maximized sensitivity and specificity, as identified
by the Youden index, showed almost identical values in the
exploratory and the validation data sets (33.3 versus 32.2,
respectively). The corresponding ARR values based on direct
renin concentration (mUI/L) and PAC (ng/dL) assay, calcu-
lated with the available App,25 were 1.75 and 1.69, respec-
tively. These values are slightly lower than those found in a
recent prospective study,26 because, in the present cohort,
the minimum PRA values were arbitrarily fixed at 0.20 ng/mL
per hour and therefore the derived direct renin concentration
led to a decrease of the estimated ARR.
We analyzed the exploratory data set at 12 ARR cutoffs
progressively increasing stepwise from 10 to 120 and found
that the positive and negative likelihood ratio and the DOR
increase progressively alongside the ARR cut-off value
(Table S3).
The results were practically identical in the validation data
set: at high ARR values, the FP rate was negligible and the
specificity approached 100% (Table 2); the positive likelihood
ratio increased exponentially alongside the DOR and tended
Table 1. Demographic Characteristics of the Patients Enrolled in the Validation Cohort
Variable PH (n=1036) P (PH vs APA) APA (n=29) P (APA vs BAH) BAH (n=11) P (BAH vs PH)
Age, y 4713 ns 4813 ns 5412 ns
Sex (M/F), % 49/51 ns 62/38 ns 73/27 ns
BMI, kg/m 277 ns 258 ns 301 ns
Systolic BP, mm Hg 14824 ns 15318 ns 15513 ns
Diastolic BP, mm Hg 9114 ns 9213 ns 8911 ns
Serum K+, mEq/L 4.00.4 <0.001 3.30.6 0.031 3.70.4 ns
Na+uV, mEq/day 158 (113–209) ns 141 (120–169) ns 177 (143–226) ns
GFR, mL/min 97 (82–112) ns 103 (90–122) ns 81 (56–108) ns
PRA, ng/mL per hour 0.90 (0.53–1.41) 0.004 0.35 (0.2–0.55) ns 0.40 (0.20–0.91) ns
PAC, ng/dL 10.0 (7.5–12.7) <0.001 28.0 (22.4–37.1) ns 18.8 (17.5–37.5) <0.001
ARR, (ng/dL)/(ng/mL per hour) 10.5 (7.1–17.5) <0.001 78.8 (51.4–137.7) <0.001 61.3 (41.2–88.4) <0.001
Data are expressed as mean valueSD or median and 25th to 75th percentile in parentheses for variables not normally distributed. APA indicates aldosterone-producing adenoma; ARR,
aldosterone-renin ratio; BAH, bilateral adrenal hyperplasia; GFR, glomerular filtration rate; K+, potassium; Na+uV, sodium urinary excretion; ns, not significant; PAC, plasma aldosterone
concentration; PH, primary (essential) hypertension; PRA, plasma renin activity.
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to infinity with ARR above 100, attributed to the fact that the
denominator entailing the odds of disease in test negatives
was 0, because all patients with an ARR above this cutoff had
an APA (Figures 2 and 4; Table 2). A sensitivity analysis
carried out using a minimum cutoff for PRA of 0.10 ng/mL
per hour (Figure S6) led to practically identical conclusions.
Diagnostic Gain of the Captopril Challenge Test
To determine the diagnostic gain of the captopril challenge
test, the ROC AUCs were compared by 2 methods: between
the baseline and the post-captopril ARR (method 1) and
between the baseline ARR and the post-captopril PAC fall
(method 2), in both cases using the APA diagnosis as
reference. This showed a negligible between-AUC difference
(0.005; 95% CI, 0.031 to 0.040; P=0.7 for comparison, and
0.009; 95% CI, 0.051 to 0.069; P=0.8, with method 1 and
method 2, respectively), indicating that the captopril chal-
lenge test provides no diagnostic gain over the baseline ARR
(Figure 3A).
Results were similar in the validation data set (between-
AUC difference, 0.05; 95% CI, 0.061 to 0.064; P=0.51 for
Table 2. Diagnostic Yield of the ARR at Specified Cutoffs in the Validation Data Set
ARR FP n (%) TN n (%) FN n (%) TP n (%) Sens. (%) Spec. (%) PLR NLR DOR ER
10 555 (51) 492 (46) 0 (0) 29 (3) 100 47 (41–53) 1.9 NA NA NA
20 213 (20) 834 (77) 1 (0) 28 (3) 97 (83–100) 80 (75–85) 4.8 0.04 110 0.20
30 81 (7) 966 (90) 1 (0) 28 (3) 97 (83–100) 92 (89–95) 12.5 0.04 334 0.08
40 39 (4) 1008 (93) 5 (1) 24 (2) 83 (55–100) 96 (94–98) 22.2 0.18 124 0.04
50 16 (1) 1031 (96) 7 (1) 22 (2) 76 (34–100) 98 (96–100) 49.6 0.25 202 0.02
60 10 (1) 1037 (96) 10 (1) 19 (2) 66 (31–100) 99 (98–100) 68.6 0.35 197 0.02
70 6 (1) 1041 (97) 12 (1) 17 (1) 59 (22–96) 99 (98–100) 102.3 0.42 246 0.02
80 4 (0) 1043 (97) 15 (1) 14 (1) 48 (11–85) 100 (99–100) 126.4 0.52 243 0.02
90 2 (0) 1045 (97) 17 (2) 12 (1) 41 (6–78) 100 (99–100) 216.6 0.59 369 0.02
100 0 (0) 1047 (97) 17 (2) 12 (1) 41 (6–78) 100 NA NA NA NA
ARR indicates aldosterone-renin ratio expressed in (ng/dL)/(ng/mL per hour); DOR, diagnostic odds ratio; ER, error rate; FN, false negative; FP, false positive; NA, not available; NLR,
negative likelihood ratio; PLR, positive likelihood ratio; sens, sensitivity; spec, specificity; TN, true negative; TP, true positive.
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Figure 3. Receiver operating characteristics (ROC) curve of baseline (BAS) and post-captopril (Capt)
aldosterone-renin ratio (ARR) for diagnosing aldosterone-producing adenoma (APA). In both the exploratory
(A) and the validation (B) cohort, the area under the curve (AUC) of the baseline and captopril ARR was
higher than the 0.500 (eg, the AUC under the identity line). However, the difference between the AUC of the
baseline and the post-captopril ARR was negligible and not statistically significant in both the exploratory
(A) and the validation (B) cohort.
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comparison with method 1; 0.02; 95% CI, 0.056 to 0.095;
P=0.6 with method 2 (Figure 3B). Of note, in the high
specificity range of values corresponding to high ARR values,
the curves were superimposed in all comparisons (Table 2,
Data S1, and Table S4).
Discussion
This study included 2 large data sets of patients that were
studied with a similar predefined protocol: the multicenter
PAPY study and a single-center validation cohort. In both
cohorts, the overall prevalence of PA was high (11.2% and
6.9%, respectively), albeit with a slightly lower difference in
the validation cohort, which reflected multiple factors. The
latter included the systematic screening of newly diag-
nosed hypertensive patients implemented at our center after
the publication of the PAPY Study,4 which led to screen a less-
selected cohort, and the tighter diagnostic criteria used.
With the strength provided by a painstaking investigation
of the patients, this study demonstrates that the baseline
(unchallenged) ARR carries essential quantitative information:
Progressively increasing ARR values implied an exponential
increase of specificity and, conversely, an exponential decay
of FP rate in both the exploratory and (even more so) in the
validation data sets. In the exploratory data set, both the
positive likelihood ratio and the DOR—a disease prevalence-
independent measure of diagnostic accuracy—were high
(6.35 and 17.7, respectively) for ARR values above 50.
Corresponding values were even higher in the validation data
set (Figure 4). Our main goal, however, was not to support
use of a given cutoff instead of another, but rather to enable
physicians to make their own choice of the ARR cutoff, and
thus of specificity, based on patient’s past probability of APA.
Hence, in Table 2, we provided the specificity, FP rate,
positive and negative likelihood ratio, and DOR values of the
validation data set as a function of the ARR values.
Noteworthy, in this study, the aforementioned Endocrine
Society guidelines’ strategy for bypassing confirmatory tests
(in patients with hypokalemia, markedly suppressed renin,
and with PAC >20 ng/dL) was feasible in only a tiny
proportion (2.5% in the exploratory cohort) of our patients.
This finding is by no means surprising inasmuch as the
existence of normoaldosteronemic APA has been well docu-
mented27,28 and hypokalemia is no longer regarded as a
conditio sine qua non of PA.4,29
The second major result of this study entails the demon-
stration that the systematic use of the captopril test provided
no diagnostic gain over baseline ARR, even in a set of patients
studied in a carefully standardized way. Comparison of the
accuracy (ROC AUC) of the baseline and post-captopril ARR
(method 1, Figure 3) or the post-captopril PAC fall (method 2)
showed no differences, not even in the portion of the ROC
curves corresponding to a high sensitivity where FP results
must be pinpointed.
Thus, overall, these findings furnished compelling evidence
that: (1) Detection of increasing ARR values are associated
with an exponential increase of the likelihood of an APA and
(2) high ARR values renders the undertaking of any further
confirmatory tests useless, if not counterproductive. This is
likely explained by the aforementioned fallacy of the premise
that all APAs are autonomous from angiotensin II.11,30,31
With the strength of a prospective design, a STARD-based
methodology funded on robust criteria to diagnose APA,19 a
large sample size, and a rigorous formal analysis, this study
therefore furnishes evidence-based support to the contention
that confirmatory tests can be skipped when the biochemical
picture of PA is florid.1,32
It might be argued that the general applicability of these
results is limited by use of the specific assays used at our
center and also by adoption of the PRA instead of the direct
concentration of (active) renin. To overcome this possible
limitation, based on the finding of a tight linear relationship
between the PRA and the direct renin concentration assay in a
large, prospective, head-to-head comparison of the 2 assays,26
the Working Group on Endocrine Hypertension of the European
Society of Hypertension has developed the ARR-App25 that
allows a swift conversion of PRA into direct renin concentra-
tion, and vice versa, and a straightforward calculation of the
ARR based on either assay. It could also be argued that the
reproducibility of the ARR is limited. However, when performed
under standardized conditions, even in a multicenter study, the
ARR was found to be within-patients reproducible33; moreover,
its reproducibility was found even higher when an automated
(hands-off) chemiluminescent assay was used.26
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Figure 4. The plot of positive likelihood ratio (LRP) and
diagnostic odds ratio (DOR) as a function of increasing aldos-
terone-renin ratio (ARR) in the validation data set. Please note
that raising ARR values are associated with an exponential
increase of both LRP and DOR.
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Some limitations of this study, however, deserve to be
mentioned before its conclusions can be generalized: our
cohorts were recruited at third-level referral centers and
therefore results need to be replicated in different settings and
to conclusively demonstrated in a randomized diagnostic trial.
Additionally, even though the cohorts comprised similar
patients, the accuracy of the ARR was slightly higher in the
validation (Figure 4) than in the exploratory data set. The
multicenter nature of the exploratory study with no centralized
biochemical assays and the single center with a centralized
measurement of all biochemical variables of the validation
study explain this finding, given that less-spread PAC, PRA, and
ARR values were found in the validation data set than in the
exploratory cohort (Figures S1 through S5). Moreover, our
study examined only whites and only the captopril challenge
test (ie, 1 of the 5 confirmatory tests for PA). Hence, we would
like to underline that our conclusions pertain to this ethnicity
and this test, which, however, is widely used and provides
results comparable to the saline infusion test if patients are
not on a low-sodium intake.11 Notwithstanding these potential
limitations, the robustness and generalizability of the following
conclusions are strongly supported by the replication of our
findings in both our large cohorts.
Conclusion
The ARR is the most used test exploited to diagnose primary
aldosteronism, the most frequent cause of curable hyperten-
sion, but is categorized as positive or negative, which means
disregarding the quantitative information that it bears. In 2
large data sets of prospectively recruited hypertensive
patients undergoing screening tests for primary aldostero-
nism, we found that high ARR values identified patients with
an exponentially increasing probability of carrying an APA and
with a likelihood of FP result approaching zero. Hence, the
ARR carries important quantitative information, which should
not be neglected by categorizing its results simply as positive
or negative. We showed that a proper use of this quantitative
information increases the diagnostic accuracy of the ARR for
identification of the surgically curable subtype of primary
aldosteronism (eg, APA). Increasing values of the ARR imply a
high positive likelihood ratio and a high DOR of APA. Above
these levels, the captopril challenge confirmatory test
furnished no diagnostic gain over the baseline ARR. Accord-
ingly, we would like to suggest that the diagnostic algorithm
can be simplified in an ample number of hypertensive patients
screened for primary aldosteronism, thus engendering an
improved case detection of APAs and, ultimately, a more cost-
effective treatment of arterial hypertension. An App that
allows calculation of the ARR25 in the unit of measure used in
this study starting from assays that measure direct active
renin concentration is a further argument supporting the
application of these findings in clinical practice.26
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Data S1. 
 
Supplemental Methods  
 
Exclusion criteria, screening procedure, pharmacological treatment, and diagnosis: The exclusion 
criteria comprised only patient’s refusal to participate in the study and a prior diagnosis of any secondary 
form of HT. Patients underwent screening while off antihypertensive treatment or, if already treated, after 
switching to calcium channels blockers and/or doxazosin following guidelines. In patients on a 
mineralocorticoid receptor antagonist (spironolactone, canrenone, or potassium canreonate), or on agents 
affecting the renin-angiotensin-aldosterone system (diuretics, beta-blockers, angiotensin-converting enzyme 
inhibitors, and angiotensin II type 1 receptor antagonists) at least six-weeks or two-weeks wash-out period 
was required, respectively. The screening test was performed after one-hour in sitting position (supine rest) 
and again 60 minutes after 50 mg oral captopril administration while the patient remained sitting (supine). It 
comprised measurement of PAC and PRA, Na+ and K+ in serum and in 24-hours urine were also assayed. 
The PAC (in ng/dl)/PRA (in ng/ml/h) ratio (ARR), at baseline and after captopril was calculated. Further 
work-up (comprising a saline infusion test, and a high-resolution computed tomography (CT) scan and/or 
magnetic resonance (MR) imaging) was performed in all patients with and ARR ≥40 baseline and/or ≥30 
post-captopril, and in one every four consecutive patients not fulfilling such criteria. All those fulfilling the 
aforementioned biochemical criteria with a positive saline infusion test underwent subtyping. AVS was used, 
if bilaterally selective, for the PA subtyping wherever available. At centers where AVS was unfeasible, 
lateralized aldosterone excess production was ascertained by dexamethasone-suppressed adrenocortical 131I-
norcholesterol scintigraphy.12 PRA was measured by radioimmunoassay with commercial kits (Ren CTK, 
Sorin Biomedica Saluggia, Italy, in 10 centers; or Angiotensin I RIA CT, Radim, Pomezia, Italy, in the 
others); intra-assay and inter-assay coefficient of variation was within 8% and 10%, respectively. PAC was 
measured with a commercial kit (Aldosterone Mirya, Technogenetics, Cassina de Pecchi, Italy; normal range 
between 10 to 150 ng/dl supine and 30 to 320 ng/dl upright on a normal Na+ diet; intra-assay and inter-
assay coefficients of variation <56%). 
Results. Diagnostic yield of the ARR at different cut-off values: to examine the diagnostic accuracy 
conveyed by the quantitative value of the ARR the exploratory dataset was analyzed at five predefined ARR 
cut-offs, which yielded high specificity (95% to 99%) and very low false positive rates decreasing stepwise 
(by 1%) from 5% to 1% (Table S4).  This analysis showed a progressive increase of the positive and negative 
likelihood ratio, and the diagnostic odds ratio alongside the ARR cut-off value (Table S4). Moreover, ARR 
values above the cut-off associated with a false positive rate of 2%, e.g. 115∙4 [in (ng/dl)/(ng/ml/h)], 
provided no incremental positive likelihood ratio (Table S4). 
Diagnostic gain of the captopril challenge test: the diagnostic gain of the captopril challenge test was also 
investigated in the exploratory dataset by selecting the 42 patients with an ARR ≥ 115∙4, e.g. positive at the 
screening test by such restrictive cut-off value.  Of them, 48∙6% of the 35 found to be positive by the PAPY 
Study criterion (e.g. post-captopril ARR > 30), were false positive (Method 1, Table S4).  
Even less accurate was the result when a post-captopril decrease of PAC < 30% (e.g. the criterion designated 
as diagnostic for APA by the Endocrine Society guidelines) in that 52.4% of the 42 positive patients were 
3 
false positive (Method 2, Table S4).  Selection of the patients with an ARR ≥ 115.4 in the exploratory or 
validation dataset also showed no diagnostic gain of the captopril challenge test over baseline ARR by using 
either Method 1 or Method 2).  In these sub-cohorts both criteria for positivity performed disappointingly 
bad, as shown by high false positive rate (0.40 and 0.52, Method 1 and 2, respectively) (Table S4), low values 
of the positive (1.10 and 1.34, for Method 1 and 2, respectively) and the negative likelihood ratio (0.55 and 
0.76, for Method 1 and 2, respectively).  The error rate was also high for both criteria (0.48 and 0.43, Method 
1 and 2, respectively) and the DOR was low (2.0 and 1.77, Method 1 and 2, respectively).  
 4 
 
 
Table S1. Demographic Characteristics of the Patients Enrolled in the PAPY Study. 
Data are expressed as mean value SD or median and 25-75 percentile in parentheses for variables not 
normally distributed. 
APA, aldosterone producing adenoma; ARR, aldosterone-renin ratio; BMI, body mass index; BP, blood 
pressure; GFR, glomerular filtration rate; BAH, idiopathic hyperaldosteronism; K+, potassium; Na+uV, 
sodium urinary excretion; ns, not significant; PAC, plasma aldosterone concentration; PH, primary 
(essential) hypertension; PRA, plasma renin activity. 
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Table S2. Demographic Characteristics of the aldosterone producing adenoma patients (n=29) of the 
Validation Cohort at baseline and after adrenalectomy. 
ARR, aldosterone-renin ratio; BMI, body mass index; BP, blood pressure; GFR, glomerular filtration rate; 
K+, potassium; Na+uV, sodium urinary excretion; ns, not significant; PAC, plasma aldosterone concentration; 
PRA, plasma renin activity. 
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Table S3. Diagnostic yield of the ARR at specified cut-offs in the exploratory dataset. 
ARR, aldosterone-renin ratio expressed in (ng/dl)/(ng/ml/h); FN, false negative; FP, false positive; TN, true 
negative; TP, true positive; DOR, diagnostic odds ratio; ER, error rate; NLR, negative likelihood ratio; PLR, 
positive likelihood ratio; NA, not available; Sens, sensitivity; Spec, specificity. 
 
  
ARR 
FP 
n (%) 
TN 
n (%) 
FN 
n (%) 
TP 
n (%) 
Sens. 
(%) 
Spec. 
(%) 
PLR NLR DOR ER 
10 
488  
(43) 
587 
(52) 
4  
(1) 
46  
(4) 
92  
(77–100) 
55  
(49–61) 
2.0 0.15 13.8 0.44 
20 
272 
(24) 
803 
(71) 
11 
(1) 
39 
(4) 
78 
(55–100) 
75 
(70–80) 
3.1 0.29 10.5 0.25 
30 
200 
(18) 
875 
(78) 
11 
(1) 
39 
(4) 
78 
(55–100) 
81 
(76–86) 
4.2 0.27 15.5 0.19 
40 
144 
(13) 
931 
(83) 
14 
(1) 
36 
(3) 
72 
(47–97) 
87 
(83–91) 
5.4 0.32 16.6 0.14 
50 
115 
(10) 
960 
(85) 
16 
(2) 
34 
(3) 
68 
(42–94) 
89 
(85–93) 
6.4 0.36 17.7 0.12 
60 
89 
(8) 
986 
(87) 
19 
(2) 
31 
(3) 
62 
(35–89) 
92 
(89–95) 
7.5 0.41 18.1 0.10 
70 
64 
(6) 
1011 
(90) 
22 
(2) 
28 
(2) 
56 
(28–84) 
94 
(91–97) 
9.4 0.47 20.1 0.08 
80 
53 
(5) 
1022 
(91) 
22 
(2) 
28 
(2) 
56 
(28–84) 
95 
(92–98) 
11.4 0.46 24.5 0.07 
90 
38 
(4) 
1037 
(92) 
25 
(2) 
25 
(2) 
50 
(22–78) 
96 
(94–98) 
14.1 0.52 27.3 0.06 
100 
30 
(3) 
1045 
(93) 
28 
(2) 
22 
(2) 
44 
(16–72) 
97 
(95–99) 
15.8 0.58 27.3 0.05 
110 
26 
(2) 
1049 
(93) 
29 
(3) 
21 
(2) 
42 
(14–70) 
98 
(96–100) 
17.4 0.59 29.2 0.05 
120 
20 
(2) 
1055 
(93) 
33 
(3) 
17 
(2) 
34 
(7–61) 
98 
(96–100) 
18.3 0.67 27.2 0.05 
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Table S4. Diagnostic yield of the captopril challenge test in the exploratory and the validation 
dataset in patients with ARR exceeding the predefined cut-off (115.4) corresponding to a 2% 
false positive rate in the exploratory dataset. 
* Method 1: test positive if post-captopril ARR ≥30; Method 2: test positive if post captopril PAC 
decrease ≤30% from baseline PAC value. 
ARR, aldosterone-renin ratio; FN, false negative; FP, false positive; TN, true negative; TP, true 
positive.  
  
Method* n 
FP 
n (%) 
TN 
N (%) 
FN 
n (%) 
TP 
n (%) 
 Exploratory dataset (n = 42) patients)  
1 42 17 (40) 5 (12) 2 (5) 18 (43) 
2 42 22 (52) 0 0 20 (48) 
 Validation dataset (n = 10 patients) 
1 10 0 0 0 10 (100) 
2 10 0 0 0 10 (100) 
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Figure S1. Age distribution in the aldosterone-producing adenoma (APA), idiopathic hyperaldosteronism (IHA), essential 
hypertension (EH) subgroups in the exploratory and validation datasets. 
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Figure S2. Glomerular filtration rate (GFR) distribution in the aldosterone-producing adenoma (APA), idiopathic 
hyperaldosteronism (IHA), essential hypertension (EH) subgroups in the exploratory and validation datasets. 
  
10 
Figure S3. Plasma renin activity (PRA) distribution in the aldosterone-producing adenoma (APA), idiopathic hyperaldosteronism 
(IHA), essential hypertension (EH) subgroups in the exploratory and validation datasets. 
11 
Figure S4. Plasma aldosterone distribution in the aldosterone-producing adenoma (APA), idiopathic hyperaldosteronism (IHA), 
essential hypertension (EH) subgroups in the exploratory and validation datasets. 
12 
Figure S5. Aldosterone-renin ratio (ARR) distribution in the aldosterone-producing adenoma (APA), idiopathic 
hyperaldosteronism (IHA), essential hypertension (EH) subgroups in the exploratory and validation datasets. 
 13 
 
Figure S6. Diagnostic yield by increasing aldosterone-renin ratio (ARR) values.  The plot shows the increase of specificity and 
false negative (FN) rate for identification of aldosterone-producing adenoma (APA) patients and the decrease of sensitivity and 
false positive (FP) rate with increasing and decreasing ARR values, respectively, in the exploratory (Upper Panel) and validation 
(Lower Panel) datasets.  Please note that ARR was computed using the minimum cutoff for PRA of 0.10 ng/mL/hr. 
